Market Signal Briefing

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc.  (Nasdaq: MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. This approval marks the first time that more than two million Americans with PSVT will have a rapid-acting treatment option they can self-administer outside the emergency department or other healthcare setting. CARDAMYST is expected to be available in retail pharmacies in the first quarter of 2026.

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT can be prepared wherever and whenever episodes occur, providing them with active management and a greater sense of control of their condition.

“CARDAMYST is a novel at-the-ready treatment option that addresses the unpredictable impact of PSVT by offering patients the freedom to manage episodes anytime and anywhere,” said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. “The FDA approval of CARDAMYST is a watershed moment for Milestone and a gratifying event for our team members, patients, clinical investigators, and health care providers who participated in the development program, all of whom I sincerely thank for their dedication, counsel, and collaboration toward this important achievement.”

“Some people with PSVT have endured years of anxiety, fearing their next episode and the stress and disruption of emergency department visits,” said James Ip, M.D., FACC, FHRS, an etripamil investigator. “CARDAMYST will give many of them the ability to administer a medication themselves that can quickly stop their PSVT episode and potentially avoid a hospital trip or a call to emergency services.”

CARDAMYST Clinical Data

The FDA approval of CARDAMYST is supported by a robust clinical trial program based on safety data from more than 1,800 participants and more than 2,000 episodes of PSVT. This includes the successful Phase 3 RAPID trial, a global, randomized, double-blind comparison of CARDAMYST vs. placebo, published in The Lancet in 2023. In clinical studies, participants using CARDAMYST were two times more likely to convert symptomatic PSVT to sinus rhythm and did so more than three times faster compared with placebo. The RAPID trial achieved its primary endpoint with 64% of those who self-administered CARDAMYST (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared to 31% on placebo (N=85) (HR = 2.62; p<0.001). At one hour, the benefit was demonstrated in 73% of participants. In addition, significant reductions in time to conversion in those who took CARDAMYST were evident early and durable, with a median time to conversion of 17 minutes (95% CI: 13.4, 26.5) for those treated with CARDAMYST vs. 54 minutes (95% CI: 38.7, 87.3) for those treated with placebo.

A consistent safety profile and treatment effects were observed across all subgroups, including participants concurrently on beta blockers or calcium channel blockers. The most frequent adverse events occurring in ≥5% of participants in randomized clinical trials were mild-to-moderate and transient in nature, including local-site nasal discomfort, nasal congestion, rhinorrhea, throat irritation, and epistaxis. Less than 2% of trial participants discontinued therapy due to adverse events.

For more safety information about CARDAMYST, please see Important Safety Information below. For the latest information about the product availability, please see https://milestonepharma.com/.

PSVT, also called SVT, is characterized by episodes of abnormally fast heart rate. Most people with PSVT experience multiple sustained episodes that require treatment on an annual basis. Until now, successful treatment options typically required IV administration in healthcare settings, creating stress and costs for patients and their insurers. CARDAMYST offers a new approach to treat episodes of PSVT, enabling adults to self-administer the medication at the onset of symptoms. For more information, please visit SVTHearttoHeart.com.

“Our goal is that CARDAMYST will become a trusted and essential solution for healthcare providers and their patients,” said Lorenz Muller, Chief Commercial Officer of Milestone. “Our team is focused on making CARDAMYST available to adults with PSVT as quickly as possible, including actively working to secure insurance coverage and begin the distribution of the product through retail pharmacies.”

Annette Greene, CARDAMYST clinical trial participant and administrator of the Supraventricular Tachycardia Group on Facebook, with more than 30,000 members, said, “Adults with SVT have been waiting a long time for the day when they can confidently self-administer CARDAMYST to treat their SVT episodes. It is very exciting that the day has become a reality.”

Regarding future R&D, Milestone is poised to enter a Phase 3 program in atrial fibrillation with rapid ventricular rate (AFib-RVR), particularly on the strength of the successful ReVeRA Phase 2 trial in AFib-RVR, results of which were published in Circulation: Arrhythmia and Electrophysiology. Incorporating FDA’s guidance, Milestone has developed a Phase 3 registrational program to evaluate self-administered etripamil as a potential treatment for patients with AFib-RVR. When completed, the Company will be following a supplemental New Drug Application (sNDA) regulatory approval pathway for a potential second indication for etripamil in AFib-RVR. As such, Milestone will leverage the approved PSVT indication and the PSVT program data, along with a single pivotal Phase 3 study in patients with AFib-RVR.

About Paroxysmal Supraventricular Tachycardia

An estimated two million people in the United States are currently diagnosed with PSVT, a type of arrhythmia or abnormal heart rhythm. PSVT is characterized by episodes of sudden onset rapid heartbeats often exceeding 150 to 200 beats per minute. The heart rate spike is unpredictable and may last several hours. The rapid heart rate often causes disabling severe palpitations, shortness of breath, chest discomfort, dizziness or lightheadedness, and distress, forcing people with PSVT to limit their daily activities. The uncertainty of when an episode of PSVT will strike or how long it will persist can provoke anxiety and negatively impact the day-to-day life between episodes of people with PSVT. The impact and morbidity from an attack can be especially detrimental in people with underlying cardiovascular or medical conditions, such as heart failure, obstructive coronary disease, or dehydration. Many health care providers are dissatisfied with the lack of effective treatment options with people with PSVT, often requiring prolonged, burdensome, and costly trips to the emergency department or even invasive cardiac ablation procedures.

About Atrial Fibrillation with Rapid Ventricular Rate

An estimated ten million Americans suffer from atrial fibrillation (AFib), a common arrhythmia marked by an irregular, disruptive and often rapid heartbeat. A subset of patients with AFib experience episodes of abnormally high heart rate most often accompanied by palpitations, shortness of breath, dizziness, and weakness. While these episodes, known as AFib-RVR, may be treated by oral calcium channel blockers and/or beta blockers, patients frequently seek acute care in the emergency department to address symptoms. In 2016, nearly 800,000 patients were admitted to the emergency department due to AFib symptoms where treatment includes medically supervised intravenous administration of calcium channel blockers or beta blockers, or electrical cardioversion. With little available data for AFib-RVR, Milestone’s initial market research indicates that 30% to 40% of patients with AFib experience one or more symptomatic episodes of RVR per year that require treatment, suggesting a target addressable market of approximately three to four million patients in 2030 for etripamil in patients with AFib-RVR.

Indication

CARDAMYST is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.

IMPORTANT SAFETY INFORMATION FOR CARDAMYST (etripamil)

What is CARDAMYST?:

CARDAMYST is a prescription medicine used to help restore normal heart rhythm in adults who have symptoms of sudden episodes of fast heartbeat called paroxysmal supraventricular tachycardia (PSVT).

It is not known if CARDAMYST is safe and effective in children.

Do use CARDAMYST if you:

are allergic to CARDAMYST or any of its ingredients. See the Patient Information for a complete list of ingredients in CARDAMYST.have limitations in activities due to heart failure (moderate to severe heart failure).have Wolff-Parkinson-White (WPW) syndrome, Lown-Ganong-Levine syndrome, or an abnormal heart rhythm pattern called pre-excitation (delta wave) on an electrocardiogram (ECG).have sick sinus syndrome without a permanent pacemaker.have second degree or higher atrioventricular (AV) block. Before using CARDAMYST, tell your healthcare provider about all of your medical conditions, including if you:

have a history of fainting.have low blood pressure.are pregnant or plan to become pregnant. It is not known if CARDAMYST will harm your unborn baby.are breastfeeding or plan to breastfeed. It is not known if CARDAMYST passes into your breast milk. You should stop breastfeeding for 12 hours after treatment with CARDAMYST. During this time, pump and throw away your breast milk. Talk to your healthcare provider about the best way to feed your baby after using CARDAMYST. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of CARDAMYST?

CARDAMYST may cause serious side effects, including:

Fainting due to CARDAMYST effects on blood pressure, heart rate, and electrical activity of the heart. CARDAMYST may cause dizziness and fainting, especially in people with a history of fainting and certain heart problems, or people with a history of fainting during an episode of PVST. Use CARDAMYST while sitting in a safe area where you will not fall if you become dizzy or lightheaded. Lie down if you feel dizzy or lightheaded after using CARDAMYST. If fainting occurs after using CARDAMYST, caregivers should place you on your back and seek medical help. The most common side effects of CARDAMYST include:

nasal discomfortnasal congestionrunny nose throat irritationnosebleed
These are not all of the possible side effects for CARDAMYST. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see the full Prescribing Information https://milestonepharma.com/etripamilprescribinginformation.pdf for CARDAMYST.

Milestone Well-Capitalized to Launch and Commercialize CARDAMYST

Milestone is well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financing. As of September 30, 2025, Milestone had cash, cash equivalents, and short-term investments of $82.6 million. In addition in March 2023, Milestone entered into the Royalty Purchase Agreement with RTW Investments, LP and certain of its affiliates (RTW), pursuant to which RTW agreed to purchase, following the FDA approval (subject to certain conditions) of etripamil on or prior to September 30, 2025 (Approval Date), the right to receive a tiered royalty payments on the annual net product sales of etripamil in the United States, in exchange for a purchase price of $75.0 million. On July 10, 2025, Milestone amended its Royalty Purchase Agreement (the Amendment) to provide for a three-month extension of the Approval Date.

Pursuant to the Amendment, in order to receive the $75.0 million purchase price, Milestone must receive marketing approval of etripamil from the FDA on or prior to December 31, 2025, and satisfy the other customary closing conditions. Milestone anticipates that the FDA approval announced today will satisfy the requirements for Milestone to receive the $75.0 million purchase price.

Conference Call and Live Webcast

Milestone management will host a conference call and live audio webcast with slides at 8:00 a.m. ET on Monday, December 15, 2025, to discuss the FDA approval of CARDAMYST. To access the call, please dial 1-877-407-0792 (domestic) or 1-201-689-8263 (international) and refer to conference ID 13756738, or click on Call me™ link and request a return call. The Call me™ link will be made active 15 minutes prior to scheduled start time. The webcast and slides can be accessed live on this link and also on the “News & Events” page of the Milestone Corporate Website at https://milestonepharma.com/. The archived webcast will also be available on Milestone's website following the call.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone’s lead product is CARDAMYST™ (etripamil) nasal spray, a novel calcium channel blocker, which is FDA approved for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. Etripamil is also in development for the treatment of symptomatic episodic attacks associated with AFib-RVR.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “continue,” “could,” “demonstrate,” “designed,” “develop,” “estimate,” “expect,” “may,” “pending,” “plan,” “potential,” “progress,” “will”, “intend” and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone’s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: expectations on the timing of CARDAMYST for PSVT being available to patients in retail pharmacies; CARDAMYST’s potential as a novel treatment option to help patients with PSVT; Milestone’s ability to make CARDAMYST quickly available to PSVT patients following FDA approval; the success of Milestone’s launch infrastructure; the timing of patient enrollment in the Phase 3 study of etripamil for AFib-RVR and expectations regarding the Phase 3 study in patients with AFib-RVR; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone’s capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone’s filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended September 30, 2025, in each case under the caption “Risk Factors,” as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Contact: 

Investor Relations 
Kevin Gardner, [email protected] 

Media Relations 
Rebecca Novak, [email protected]  

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1cd3bcec-2019-4e39-b90e-aab21bcd97ac.

December 12, 2025 20:00 ET

 | Source:

Nasdaq, Inc.

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025.

The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), Ferrovial SE (Nasdaq: FER), Insmed Incorporated (Nasdaq: INSM), Monolithic Power Systems, Inc. (Nasdaq: MPWR), Seagate Technology Holdings plc (Nasdaq: STX), Western Digital Corp. (Nasdaq: WDC).

The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassing a diverse range of industries and sectors. From technology and retail to healthcare, telecommunications, biotechnology, and media, these companies collectively shape the new 21st century economy. The Nasdaq-100® is reconstituted each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.

As of December 2025, the Nasdaq-100 Index underpins more than 200 tracking products with over $600 billion in assets under management globally, including the Invesco QQQ Trust (QQQ®), which seeks to deliver investment results that, before expenses, correspond to the performance of the Nasdaq-100 Index. In addition to QQQ, a range of derivatives and structured instruments, such as futures, options, and other products based on the Nasdaq-100 Index and the Invesco QQQ Trust trade on various exchanges.

As a result of the reconstitution, the following six companies will be removed from the Index: Biogen Inc. (Nasdaq: BIIB), CDW Corporation (Nasdaq: CDW), GlobalFoundries Inc. (Nasdaq: GFS), Lululemon Athletica Inc. (Nasdaq: LULU), ON Semiconductor Corporation (Nasdaq: ON), The Trade Desk, Inc. (Nasdaq: TTD).

Information

For information about the six companies to be added to the Nasdaq-100 Index, please visit the following respective company websites:

Alnylam Pharmaceuticals, Inc. – https://www.alnylam.com/Ferrovial SE – https://www.ferrovial.com/Insmed Incorporated – https://insmed.com/Monolithic Power Systems, Inc. – https://www.monolithicpower.com/Seagate Technology Holdings plc – https://www.seagate.com/Western Digital Corp. – https://www.westerndigital.com/ About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com

Nasdaq®, Nasdaq-100 Index®, Nasdaq-100®, NDX®, QQQ®, and Nasdaq Stock Market® are registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

NDAQF

Alan Imberman, CFO of Wealthfront (WLTH), joins the Watch List after the company made its public trading debut Friday. He talks about how the fintech company is capitalizing on the digital landscape and how it collected a 1.3 million client base.

Rebounding further off its multi-year lows, Lululemon (LULU - Free Report)  stock spiked as much as +14% in Friday’s trading session after delivering stronger-than-expected Q3 results yesterday evening and providing favorable guidance.

Still trading more than 50% from a 52-week high of $423 a share, Lululemon’s Q3 report helped to calm fears of slower demand in its core U.S. market, along with tariff and inflation-related pressures that have squeezed margins.

Further boosting investor confidence regarding its long-term value, the retail apparel leader authorized a $1 billion stock repurchase plan. Lululemon also announced its current CEO, Calvin McDonald, will step down by January, with the succession plan being welcomed after a challenging year.

Image Source: Zacks Investment Research

International Expansion Drives Strong Q3 ResultsDriven by strong international growth, Lululemon’s Q3 sales increased 7% year over year to $2.56 billion, exceeding estimates of $2.48 billion by 3%. Asia and Europe fueled the growth in particular, showing Lululemon’s brand strength outside North America, with international markets revenue increasing 33% while seeing 18% comparable store sales growth.

Americas segment sales dipped 2%, with comparable store sales down 5%. However, another positive highlight included global digital sales of $1.1 billion, a 13% increase from Q3 2024, and contributing to 42% of total revenue for the quarter. 

On the bottom line, Q3 EPS of $2.59 came in 16% above expectations of $2.22 despite declining from $2.87 per share a year ago. 

Lululemon's Raised GuidanceRaising its full-year guidance, Lululemon now expects annual sales at $10.96-$11.05 billion, up from prior forecasts of $10.85-$11 billion and above the current Zacks Consensus of $10.95 billion or 3% growth. EPS targets were increased to a range of $12.92-$13.02, from earlier guidance of $12.77-$12.97 and above consensus estimates of $12.91, or a 12% decrease.

Tracking Lululemon’s Operational Efficiency  Lululemon’s operating margins slipped to 17%, down from 20.5% in the comparative quarter. That said, Lululemon’s store expansion correlates with its high return on invested capital (ROIC) of 32%. Lululemon opened 14 new stores during Q3, bringing its total store count to 730 globally.

Lululemon’s ROIC has wavered in recent years, but the overall uptick from a 20% ROIC in 2021 also indicates the company has continued to use its capital very efficiently to generate profits.

Image Source: Zacks Investment Research

It is important to note, though, that Lululemon’s free cash flow conversion rate has fallen below the preferred range of 80% or higher (72.9%), making its cash generation look weak relative to its net income. The lower FCF conversion signals that reported profits aren’t fully translating into cash and is often seen in companies that are expanding rapidly and have cash tied up in receivables, inventory, or capital expenditures.

Image Source: Zacks Investment Research

Conclusion & Final Thoughts Following its stronger-than-expected Q3 report, Lululemon's stock lands a Zacks Rank #3 (Hold). While Lululemon hasn’t set the alarm off regarding liquidity concerns and has a relatively strong balance sheet, the apparel leader is no longer in the top tier of quality companies in terms of operatinal efficiency.

Still, the increasing ROIC is promising, and hopefully, Lululemon’s international and digital sales expansion will help the company get back on track to the stellar growth that captivated investors in the past. At current levels, Lululemon’s reasonable valuation of 14X forward earnings is attractive to long-term investors as well, even if better buying opportunities are ahead after the post-earnings rally.

December 12, 2025 8:13 PM EST | Source: Canadian Critical Minerals Inc.
Calgary, Alberta--(Newsfile Corp. - December 12, 2025) - Canadian Critical Minerals Corp. (TSXV: CCMI) (OTCQB: RIINF) ("CCMI" or the "Company") is pleased to announce it has closed the first tranche of its previously announced private placement for gross proceeds of $588,850 through the issuance of 16,824,286 units of the Company (each, a "Unit") at a price of $0.035 per Unit (the "Offering").

Each Unit is comprised of one common share of the Company (a "Common Share") and one common share purchase warrant of the Company (a "Warrant"), with each Warrant exercisable into one Common Share at a price of $0.05 for a period of five (5) years.

The Company expects to complete a second tranche of the Offering next week. The Offering remains subject to the final approval of the TSX Venture Exchange.

In accordance with National Instrument 45-106 - Prospectus Exemptions ("NI 45-106"), the Units were issued to Canadian purchasers pursuant to the listed issuer financing exemption under Part 5A of NI 45-106, as amended by Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the "Listed Issuer Financing Exemption"). The Common Shares and Warrants issued to purchasers resident in Canada are immediately freely tradeable in accordance with applicable Canadian securities laws.

There is an offering document related to the Offering and the use by the Company of the Listed Issuer Financing Exemption that can be accessed under the Company's profile on SEDAR+ at www.sedarplus.ca and on the Company's website at www.canadiancriticalmineralsinc.com.

In connection with the Offering, the Company paid finders fees of $2,401 and 68,600 finders warrants with each finder warrant entitling the holder thereof to purchase one common share at a price of $0.05 for a period of two years. The finder warrants and the underlying common shares are subject to a four month and one day hold period from the closing date of the Offering in accordance with applicable Canadian securities laws.

The Company intends to use the proceeds of the Offering to complete its application to restart the Bull River Mine project near Cranbrook, BC. and for working capital.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

About CCMI
CCMI is a mining company primarily focused on copper production assets in Canada. CCMI's main asset is the 100% owned Bull River Mine project (150 million lbs of copper) near Cranbrook, British Columbia which has a Mineral Resource containing copper, gold and silver. CCMI also owns a 5.3% interest in XXIX Metal Corp. which holds a 100% interest in the Thierry copper project near Pickle Lake, Ontario and a 100% interest in the Opemiska copper project near Chapais-Chibougamau, Quebec.

Cautionary Statement Regarding Forward-Looking Information

This news release contains certain "forward-looking information" within the meaning of Canadian securities legislation, including, but not limited to, statements regarding the Company's plans with respect to the Company's projects and the timing related thereto, the merits of the Company's projects, the Company's objectives, plans and strategies, the use of proceeds of the Offering and other matters. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective,", "strategy", "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Except to the extent required by applicable securities laws and the policies of the TSX Venture Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors, should change. Factors that could cause future results to differ materially from those anticipated in these forward- looking statements include the risk of accidents and other risks associated with mineral exploration operations, the risk that the Company will encounter unanticipated geological factors, or the possibility that the Company may not be able to secure permitting and other agency or governmental clearances, necessary to carry out the Company's exploration plans, risks of political uncertainties and regulatory or legal changes in the jurisdictions where the Company carries on its business that might interfere with the Company's business and prospects. The reader is urged to refer to the Company's reports, publicly available through the Canadian Securities Administrators' System for Electronic Data Analysis and Retrieval + (SEDAR+) at www.sedarplus.ca for a more complete discussion of such risk factors and their potential effects.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Not for distribution to United States newswire services or for dissemination in the United States

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277977

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CGNT either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Are investors ready to buy into Rivian's vision for its autonomous vehicles and AI?

In the latest trading session, Cloudflare (NET - Free Report) closed at $202.44, marking a -2.65% move from the previous day. This change lagged the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.51%, while the tech-heavy Nasdaq lost 1.69%.

Coming into today, shares of the web security and content delivery company had lost 2.62% in the past month. In that same time, the Computer and Technology sector gained 1.6%, while the S&P 500 gained 0.94%.

The investment community will be closely monitoring the performance of Cloudflare in its forthcoming earnings report. On that day, Cloudflare is projected to report earnings of $0.27 per share, which would represent year-over-year growth of 42.11%. In the meantime, our current consensus estimate forecasts the revenue to be $589.23 million, indicating a 28.11% growth compared to the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $0.91 per share and a revenue of $2.14 billion, indicating changes of +21.33% and +28.33%, respectively, from the former year.

Investors should also take note of any recent adjustments to analyst estimates for Cloudflare. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 2.07% higher within the past month. Cloudflare presently features a Zacks Rank of #2 (Buy).

Valuation is also important, so investors should note that Cloudflare has a Forward P/E ratio of 229.66 right now. This valuation marks a premium compared to its industry average Forward P/E of 29.42.

Also, we should mention that NET has a PEG ratio of 8.56. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. As the market closed yesterday, the Internet - Software industry was having an average PEG ratio of 1.98.

The Internet - Software industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 57, this industry ranks in the top 24% of all industries, numbering over 250.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

In the latest trading session, Gold.com (GOLD - Free Report) closed at $31.72, marking a +1.08% move from the previous day. The stock's performance was ahead of the S&P 500's daily loss of 1.07%. On the other hand, the Dow registered a loss of 0.51%, and the technology-centric Nasdaq decreased by 1.69%.

The stock of precious metals trading company has risen by 23.4% in the past month, leading the Finance sector's gain of 2.46% and the S&P 500's gain of 0.94%.

Investors will be eagerly watching for the performance of Gold.com in its upcoming earnings disclosure. The company is expected to report EPS of $0.7, up 27.27% from the prior-year quarter. In the meantime, our current consensus estimate forecasts the revenue to be $2.73 billion, indicating a 0.52% decline compared to the corresponding quarter of the prior year.

For the full year, the Zacks Consensus Estimates project earnings of $2.8 per share and a revenue of $12.01 billion, demonstrating changes of +29.03% and +9.37%, respectively, from the preceding year.

Any recent changes to analyst estimates for Gold.com should also be noted by investors. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research shows that these estimate changes are directly correlated with near-term stock prices. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Gold.com boasts a Zacks Rank of #5 (Strong Sell).

In terms of valuation, Gold.com is presently being traded at a Forward P/E ratio of 11.21. This represents a discount compared to its industry average Forward P/E of 12.42.

The Financial - Miscellaneous Services industry is part of the Finance sector. Currently, this industry holds a Zacks Industry Rank of 85, positioning it in the top 35% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Brinker International (EAT - Free Report) closed the most recent trading day at $144.45, moving +1.35% from the previous trading session. The stock outperformed the S&P 500, which registered a daily loss of 1.07%. Meanwhile, the Dow experienced a drop of 0.51%, and the technology-dominated Nasdaq saw a decrease of 1.69%.

Shares of the operator of restaurant chains Chili's Grill & Bar and Maggiano's Little Italy witnessed a gain of 21.65% over the previous month, beating the performance of the Retail-Wholesale sector with its loss of 1.03%, and the S&P 500's gain of 0.94%.

The investment community will be closely monitoring the performance of Brinker International in its forthcoming earnings report. On that day, Brinker International is projected to report earnings of $2.5 per share, which would represent a year-over-year decline of 10.71%. At the same time, our most recent consensus estimate is projecting a revenue of $1.4 billion, reflecting a 2.83% rise from the equivalent quarter last year.

For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of $10.2 per share and a revenue of $5.73 billion, representing changes of +14.61% and +6.35%, respectively, from the prior year.

It's also important for investors to be aware of any recent modifications to analyst estimates for Brinker International. Recent revisions tend to reflect the latest near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.27% higher. Right now, Brinker International possesses a Zacks Rank of #3 (Hold).

Digging into valuation, Brinker International currently has a Forward P/E ratio of 13.97. For comparison, its industry has an average Forward P/E of 21.08, which means Brinker International is trading at a discount to the group.

Investors should also note that EAT has a PEG ratio of 0.98 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As the market closed yesterday, the Retail - Restaurants industry was having an average PEG ratio of 2.3.

The Retail - Restaurants industry is part of the Retail-Wholesale sector. Currently, this industry holds a Zacks Industry Rank of 187, positioning it in the bottom 25% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Stride, Inc. (NYSE: LRN) between October 22, 2024 and October 28, 2025, both dates inclusive (the “Class Period”), of the important January 12, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Stride securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Stride class action, go to https://rosenlegal.com/submit-form/?case_id=30689 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 12, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, during the Class Period, defendants made misleading statements and omissions regarding Stride’s products and services to public and private schools, school district, and charter boards. Throughout the Class Period, Stride represented to investors that “[t]hese products and services, spanning curriculum, systems, instruction, and support services are designed to help learners of all ages reach their full potential through inspired teaching and personalized learning.” Unbeknownst to investors, Stride was inflating enrollment numbers, cutting staff costs beyond required statutory limits, ignoring compliance requirements, and losing existing and potential enrollments. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Stride class action, go to https://rosenlegal.com/submit-form/?case_id=30689 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

, /PRNewswire/ -- Ferrovial SE ("Ferrovial" or the "Company", Ticker: "FER") announces that it has resolved to terminate, with effect from today's closing of the U.S. stock exchanges, the ongoing buyback program announced to the market on 14 March 2025 and commenced on 2 June 2025 (the "Current Program"). In accordance with applicable regulations, Ferrovial will provide details of the final repurchases of Ferrovial shares under the Current Program, including the total number of shares acquired and the total amount invested under the Current Program.    

Ferrovial also announces, in accordance with the authorization granted by the Company's general meeting held on 24 April 2025 under agenda item 10, that it has resolved to implement a new repurchase program of its shares (the "New Repurchase Program").

The New Repurchase Program will have the following characteristics:

(i) Purpose: To repurchase Ferrovial shares in the context of actions related to future projects consistent with the strategic objectives the Company intends to pursue, for industrial projects, or other transactions or corporate actions involving the assignment or disposition of treasury shares.

(ii) Maximum investment: EUR 800 million. In no case may the number of shares to be acquired under the New Repurchase Program exceed 15 million Ferrovial shares, representing approximately 2.04% of Ferrovial's issued share capital as of the date of this announcement.

(iii) Price and volume conditions: The shares will be acquired in accordance with the relevant authorization of the Company's general meeting.

Moreover, although the New Repurchase Program does not constitute a buyback program under Regulation (EU) No. 596/2014, of the European Parliament and of the Council, of 16 April, on market abuse, and its developing regulations, on the European markets, Ferrovial will not purchase shares at a price exceeding the higher of the following amounts: (a) the price of the last independent trade; or (b) the amount corresponding to the highest current independent purchase bid on the trading venue where the purchase is carried out. As regards volume, the Ferrovial will not purchase on any trading day more than 25% of the average daily volume of Ferrovial shares traded on the trading venue on which the purchase is carried out. The average daily volume of the Company's shares for the purposes of the aforementioned calculation will be based on the average daily volume traded in the twenty (20) trading days preceding the date of every purchase.

On the U.S. markets, Ferrovial shares will be acquired in accordance with the applicable U.S. federal securities laws.

(iv) Duration: The New Repurchase Program has been authorized for the period from 15 December 2025 up to 15 October 2026 (both dates included), without prejudice to the Company's ability to extend the program's duration in view of the prevailing circumstances and in the interest of the Company and its stakeholders. Likewise, Ferrovial reserves the right to terminate the New Repurchase Program, in accordance with applicable law, if, prior to its term, it has reached the maximum investment amount or the maximum number of shares authorized, or if any other circumstance makes it advisable to do so.

(v) Disclosures: Any amendments to the New Repurchase Program, as well as the transactions carried out, will be disclosed to the competent authority of the most relevant market in terms of liquidity as referred to in Article 26(1) of Regulation (EU) No 600/2014 (or any other regulatory authority to which, as the case may be, must be disclosed).

Transactions under the New Repurchase Program will also be published on the Company's website.

(vi) Broker: Goldman Sachs has been engaged to carry out purchases under the New Repurchase Program. Goldman Sachs will make the purchases on the Company's behalf and make all trading decisions independently of Ferrovial.

Forward-looking statements

This announcement contains forward-looking statements, which include statements with respect to the Ferrovial's share repurchase program, including its expected duration, maximum investment and purpose. Any express or implied statements contained in this announcement that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements that include the words "expect," "will," "intend," "plan," "believe," "project," "forecast," "estimate," "may," "should," "anticipate" and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: risks related to our diverse geographical operations; risks related to our acquisitions, divestments and other strategic transactions that we may undertake; the impact of competitive pressures in our industry and pricing, including the lack of certainty and costs in winning competitive tender processes; general economic and political conditions and events and the impact they may have on us, including, but not limited to, volatility or increases in inflation rates and rates of interest, increased costs and availability of materials, and other ongoing impacts resulting from circumstances including changes in tariff regimes, the Russia/Ukraine conflict, and the Middle East conflict; the fact that our business is derived from a small number of major projects; cyber threats or other technology disruptions; our ability to obtain adequate financing in the future as needed; our approach to dividend or other distribution determinations and the  ability to pay dividends at current levels; our ability to maintain compliance with the continued listing requirements of Euronext Amsterdam, the Nasdaq Global Select Market and the Spanish Stock Exchanges; lawsuits and other claims by third parties or investigations by various regulatory agencies that we may be subject to; our ability to comply with our ESG commitments or other sustainability demands; the impact of any changes governmental laws and regulations, including but not limited to tax regimes or regulations; and the other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC") for the fiscal year ended December 31, 2024 which is available on the SEC website at www.sec.gov, as such factors may be updated from time to time in our other filings with the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof and accordingly undue reliance should not be placed on such statements. We disclaim any obligation or undertaking to update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law. Forward-looking statements in this announcement are made pursuant to the safe harbor provisions contained in the U.S. Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by relevant safe harbor provisions for forward-looking statements (or their equivalent) of any applicable jurisdiction.  

About Ferrovial 

Ferrovial is one of the world's leading infrastructure companies. The Company operates in more than 15 countries and has a workforce of over 25,000 worldwide. Ferrovial is triple listed on Euronext Amsterdam, the Spanish Stock Exchanges and Nasdaq and is a member of Spain's blue-chip IBEX 35 index. It is also included in globally recognized sustainability indices such as the Dow Jones Best in Class Index (former Dow Jones Sustainability Index) and strives to conduct its operations in compliance with the principles of the UN Global Compact, which the Company adopted in 2002.

SOURCE Ferrovial

Teradyne (TER - Free Report) closed the most recent trading day at $193.37, moving -5.2% from the previous trading session. The stock fell short of the S&P 500, which registered a loss of 1.07% for the day. On the other hand, the Dow registered a loss of 0.51%, and the technology-centric Nasdaq decreased by 1.69%.

The stock of maker of wireless products, data storage and equipment to test semiconductors has risen by 20.27% in the past month, leading the Computer and Technology sector's gain of 1.6% and the S&P 500's gain of 0.94%.

The investment community will be closely monitoring the performance of Teradyne in its forthcoming earnings report. The company's upcoming EPS is projected at $1.36, signifying a 43.16% increase compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $970.1 million, indicating a 28.85% upward movement from the same quarter last year.

For the full year, the Zacks Consensus Estimates are projecting earnings of $3.51 per share and revenue of $3.05 billion, which would represent changes of +9.01% and +8.06%, respectively, from the prior year.

Any recent changes to analyst estimates for Teradyne should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.

Our research reveals that these estimate alterations are directly linked with the stock price performance in the near future. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 1.41% rise in the Zacks Consensus EPS estimate. Currently, Teradyne is carrying a Zacks Rank of #2 (Buy).

Looking at its valuation, Teradyne is holding a Forward P/E ratio of 58.13. This indicates a premium in contrast to its industry's Forward P/E of 24.48.

We can additionally observe that TER currently boasts a PEG ratio of 2.13. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. By the end of yesterday's trading, the Electronics - Miscellaneous Products industry had an average PEG ratio of 1.95.

The Electronics - Miscellaneous Products industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Paccar (PCAR - Free Report) closed at $111.56 in the latest trading session, marking a -1.09% move from the prior day. This change lagged the S&P 500's daily loss of 1.07%. Meanwhile, the Dow lost 0.51%, and the Nasdaq, a tech-heavy index, lost 1.69%.

Shares of the truck maker have appreciated by 16.82% over the course of the past month, outperforming the Auto-Tires-Trucks sector's gain of 1.87%, and the S&P 500's gain of 0.94%.

Analysts and investors alike will be keeping a close eye on the performance of Paccar in its upcoming earnings disclosure. The company's earnings per share (EPS) are projected to be $1.05, reflecting a 36.75% decrease from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $6.06 billion, indicating a 17.64% decline compared to the corresponding quarter of the prior year.

Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of $5.01 per share and revenue of $26.05 billion. These totals would mark changes of -36.58% and -17.48%, respectively, from last year.

Investors should also take note of any recent adjustments to analyst estimates for Paccar. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.49% lower within the past month. Paccar is holding a Zacks Rank of #3 (Hold) right now.

Investors should also note Paccar's current valuation metrics, including its Forward P/E ratio of 22.53. This signifies a premium in comparison to the average Forward P/E of 16.65 for its industry.

We can also see that PCAR currently has a PEG ratio of 15.43. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As of the close of trade yesterday, the Automotive - Domestic industry held an average PEG ratio of 1.92.

The Automotive - Domestic industry is part of the Auto-Tires-Trucks sector. Currently, this industry holds a Zacks Industry Rank of 67, positioning it in the top 28% of all 250+ industries.

The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.

December 12, 2025 7:12 PM EST | Source: Metalero Mining Corp.
Edmonton, Alberta--(Newsfile Corp. - December 12, 2025) - Metalero Mining Corp. (TSXV: MLO) (OTC Pink: CRTTF) ("Metalero" or the "Company") is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement (the "Offering").

The second tranche consisted of 517,523 flow-through units (the "FT Units") at a price of $0.21 per FT Unit, for total gross proceeds of $108,679.83. Each Unit consists of one (1) flow-through common share (a "FT Share") and one (1) common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to purchase one (1) additional non flow-through common share at a price of $0.26 for two (2) years from the date of issuance.

In connection with the sale of these FT Units, Metalero paid a total of $8,694 in cash and issued 41,402 non-transferable finder's warrants ("Finder's Warrants") to eligible finders for certain of the FT Units sold. Each Finder's Warrant entitles the holder to purchase one (1) common share of Metalero at a price of $0.21 per share, for up to two (2) years from the date of issuance.

The proceeds will be used to support the Fall/Winter 2025 and early 2026 exploration work at Benson including further sampling and ground geophysics. All securities issued are subject to a hold period until April 13, 2026.

All FT Shares offered in connection with this Offering qualify as a "flow-through share" within the meaning of the Income Tax Act (Canada) (the "Tax Act"). For subscribers who are qualifying individuals under the Income Tax Act (British Columbia) (the "BC Tax Act"), these expenditures will also qualify as "BC flow-through mining expenditures", as defined in section 4.721(1) of the BC Tax Act.

For additional information with respect to this Offering, please refer to Metalero's news releases dated September 25, 2025, October 10, 2025, October 22, 2025 and November 21, 2025, available for viewing on Metalero's SEDAR+ profile (www.sedarplus.ca).

Benson Project Background

Situated in the Quesnel Trough, one of Canada's most important mineral belts, the Benson Project is a strategically significant asset that Metalero has the right to acquire in its entirety. The Quesnel Trough is a Triassic/Jurassic-age belt of volcano-sedimentary and intrusive rocks which hosts >360 alkalic copper-gold porphyry occurrences and deposits. At >1,500 km long, the Quesnel Trough runs through the middle of BC stretching from the US to the Yukon Territory. It hosts numerous major mines which produce copper and gold as well as variable amounts of silver and molybdenum while also hosting several types of gold deposits.

High profile and long-lived mines in the Quesnel Trough include Highland Valley, Mt Milligan, New Afton and Kemess which are complemented by recent exploration work including Woodjam, MPD, Kwanika, and the extensive staking by Australian mining giant, the Fortescue Group.

The Benson Project lies close to infrastructure and is traversed by Highway 26 and a vast network of logging roads allowing for ready access to all parts of the Property and capital-efficient exploration. The large land package covers 5 different target areas illuminated by recent Artificial-Intelligence ("AI") work by Geoscience BC (Mitchinson et al., Geoscience BC Report 2022-07). This AI study incorporated a wide variety of historical datasets including geophysics, geology, sampling information, and drilling data (where present) to identify high potential ("porphyry-like") anomalies with similarities to known porphyry deposits elsewhere in the belt. Even the limited historical exploration at Benson has identified numerous gold and copper surface geochemical anomalies while modest, historical drill programs have intersected skarn and epithermal gold and silver mineralization, which are both intrusive-related styles of mineralization and are commonly associated with porphyry systems.

About Metalero Mining Corp.

Metalero Mining Corp. is a Canadian-based junior exploration company focused on copper and gold projects in North America. Its 173 square kilometer, road-accessible Benson Project serves as Metalero's flagship and is host to five prospects containing gold and copper within porphyry-related mineralized systems.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-Looking Statements This news release may contain certain "forward looking statements" or "forward-looking information" within the meaning of applicable securities laws including, without limitation, the timing, nature, scope and details regarding the Company's exploration plans and results. Such statements and information involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, its projects, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. Such statements can be identified by the use of words such as "may", "would", "could", "will", "intend", "expect", "believe", "plan", "anticipate", "estimate", "scheduled", "forecast", "predict" and other similar terminology, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. These statements reflect the company's current expectations regarding future events, performance and results and speak only as of the date of this release.

Forward-looking statements in this press release are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. These include, but are not limited to, structure and terms of the Offering, the anticipated closing date(s) of the Offering, the intended use of proceeds of the Offerings, and approval of the Offerings by the TSX-V, risks associated with the mining industry in general, the exploration and development of mineral properties, the Company's ability to obtain necessary financing, and general economic, market or business conditions. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. All forward looking information contained in this press release is given as of the date hereof and is based upon the opinions and estimates of management and information available to management as at the date hereof. Other factors which could materially affect such forward-looking information are described in the risk factors in the Company's most recent annual management's discussion and analysis which is available on the Company's profile on SEDAR+ at www.sedarplus.ca. Metalero disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.

Not for distribution to United States newswire services or for dissemination in the United States.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277969

Onto Innovation (ONTO - Free Report) ended the recent trading session at $156.36, demonstrating a -2.5% change from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.51%, while the tech-heavy Nasdaq lost 1.69%.

The maker of semiconductor manufacturing equipment's stock has climbed by 23.62% in the past month, exceeding the Computer and Technology sector's gain of 1.6% and the S&P 500's gain of 0.94%.

Analysts and investors alike will be keeping a close eye on the performance of Onto Innovation in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.27, showcasing a 15.89% downward movement from the corresponding quarter of the prior year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $266.11 million, up 0.82% from the year-ago period.

For the full year, the Zacks Consensus Estimates are projecting earnings of $4.96 per share and revenue of $1 billion, which would represent changes of -7.12% and +1.74%, respectively, from the prior year.

Any recent changes to analyst estimates for Onto Innovation should also be noted by investors. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.

The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.9% higher. Onto Innovation currently has a Zacks Rank of #2 (Buy).

In terms of valuation, Onto Innovation is presently being traded at a Forward P/E ratio of 32.33. This represents no noticeable deviation compared to its industry average Forward P/E of 32.33.

We can also see that ONTO currently has a PEG ratio of 1.08. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. ONTO's industry had an average PEG ratio of 1.08 as of yesterday's close.

The Nanotechnology industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 6, this industry ranks in the top 3% of all industries, numbering over 250.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

In the latest close session, Dynatrace (DT - Free Report) was up +1.68% at $46.04. The stock outpaced the S&P 500's daily loss of 1.07%. Elsewhere, the Dow lost 0.51%, while the tech-heavy Nasdaq lost 1.69%.

Shares of the software intellegence company witnessed a loss of 3.21% over the previous month, trailing the performance of the Computer and Technology sector with its gain of 1.6%, and the S&P 500's gain of 0.94%.

The upcoming earnings release of Dynatrace will be of great interest to investors. The company's upcoming EPS is projected at $0.41, signifying a 10.81% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $505.77 million, up 15.96% from the prior-year quarter.

For the full year, the Zacks Consensus Estimates project earnings of $1.63 per share and a revenue of $1.99 billion, demonstrating changes of +17.27% and +17.21%, respectively, from the preceding year.

It is also important to note the recent changes to analyst estimates for Dynatrace. These recent revisions tend to reflect the evolving nature of short-term business trends. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, there's been a 0.09% fall in the Zacks Consensus EPS estimate. As of now, Dynatrace holds a Zacks Rank of #3 (Hold).

In terms of valuation, Dynatrace is currently trading at a Forward P/E ratio of 27.74. This signifies a premium in comparison to the average Forward P/E of 16.72 for its industry.

It's also important to note that DT currently trades at a PEG ratio of 1.96. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Computers - IT Services industry was having an average PEG ratio of 1.93.

The Computers - IT Services industry is part of the Computer and Technology sector. This group has a Zacks Industry Rank of 91, putting it in the top 37% of all 250+ industries.

The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.

Resources

Investor Relations

Journalists

Agencies

Client Login

Send a Release

News

Products

Contact

, /PRNewswire/ -- Corebridge Financial Inc. (NYSE: CRBG) will replace Allete Inc. (NYSE: ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions.

Following is a summary of the change that will take place prior to the open of trading on the effective date:

Effective Date

Index Name

Action

Company Name

Ticker

GICS Sector

Dec 17, 2025

S&P MidCap 400

Addition

Corebridge Financial

CRBG

Financials

Dec 17, 2025

S&P MidCap 400

Deletion

Allete

ALE

Utilities

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spglobal.com/spdji/en/. 

FOR MORE INFORMATION:

S&P Dow Jones Indices
[email protected]

Media Inquiries
[email protected]

SOURCE S&P Dow Jones Indices

Analyst’s Disclosure:I/we have a beneficial long position in the shares of HOV, HOVNP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Key Takeaways
Oracle shares dropped Friday following reports it had delayed delivery of some data centers for OpenAI.The stock ended the week nearly 13% lower after Oracle's quarterly results on Wednesday fell short of expectations and amplified scrutiny of its AI investments.

A bad week for software maker Oracle (ORCL) ended on a sour note. 

Bloomberg, citing people familiar with the matter, reported that Oracle had delayed by a year the delivery of some data centers it's developing for ChatGPT maker OpenAI. The delays were caused by material and labor shortages, according to Bloomberg.

The report weighed on Oracle's shares, already under pressure following the release of its results earlier in the week, pulling them another 4.5% lower Friday to levels not seen since June.

The company in a statement said "all milestones remain on track."

Why This Is Important
Oracle is borrowing heavily in its bid to compete with cloud computing giants like Microsoft and Alphabet. That has made investors wary of the software giant's data center investments.

“There have been no delays to any sites required to meet our contractual commitments,” an Oracle spokesperson told Investopedia. “We remain fully aligned with OpenAI and confident in our ability to execute against both our contractual commitments and future expansion plans.”

Friday’s losses extended Oracle stock’s Thursday drop, when shares tumbled more than 10% after the company’s quarterly earnings fell short of expectations and revived concerns about its AI ambitions. Oracle stock lost nearly 13% of its value this week. 

Oracle is aggressively investing in AI infrastructure to compete with cloud computing incumbents Microsoft (MSFT), Alphabet (GOOG), and Amazon (AMZN). However, unlike its largest competitors, whose profits are paying for their data center projects, Oracle is borrowing heavily. Some investors are concerned the company will struggle to repay its debt if AI demand falls short of expectations. 

Oracle’s business with OpenAI has added to investor concerns. OpenAI accounts for $300 billion, or more than half, of Oracle’s cloud computing backlog, but the start-up isn’t expected to turn a profit until the end of the decade.

Whether Oracle realizes all of its future revenue from OpenAI will depend to some extent on the latter’s ability to raise money from investors or lenders. 

Do you have a news tip for Investopedia reporters? Please email us at

[email protected]

'Fast Money' trader Tim Seymour talks the jump in cannabis stocks on reclassification rumors.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your DeFi Technologies (“DeFi” or the “Company”) (NASDAQ:DEFT) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [email protected], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until January 30, 2026 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Is The Lawsuit A.

- NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES -

December 12, 2025 18:00 ET

 | Source:

North American Niobium and Critical Minerals Corp.

Vancouver, BC, Dec. 12, 2025 (GLOBE NEWSWIRE) -- North America Niobium and Critical Minerals Corp. (CSE: NIOB) (FSE: IOR) (OTCQB: NIOMF) (“North American Niobium” or the “Company”) is pleased to announce, further to its news release of December 4, 2025, that the Company has closed the previously announced non-brokered private placement of flow-through common shares in the capital of the Company (each, an “FT Share”) by the issuance of 1,351,955 FT Shares at $1.45 per FT Share for gross proceeds of $1,960,334.75, exceeding the proposed amount previously announced (the “Oversubscribed Offering”)

The gross proceeds from the issuance of the FT Shares will be used to incur eligible “Canadian exploration expenses” in Quebec that qualify as “flow-through critical mineral mining expenditures” as such terms are defined in the Income Tax Act (Canada). The Company has agreed to renounce such qualifying expenditures with an effective date of no later than December 31, 2025, in an amount of not less than the total amount of the gross proceeds raised from the issuance of FT Shares, and incur such expenses by December 31, 2026.

In connection with the Oversubscribed Offering, the Company paid finder’s fees to eligible finders consisting of $137,223.43 in cash and 94,636 common share purchase warrants (the “Finder’s Warrants”). Each Finder’s Warrant is exercisable to acquire one common share in the capital of the Company at an exercise price of $1.45 for a period of 24 months from the date of issuance.

“The overwhelming demand for this financing is a reflection of the strength of the work we’re doing and the potential that our Quebec exploration portfolio continues to show. With total flow-through funding of $4.82 million secured for our 2026 exploration program, we are well positioned to execute focused and strategic exploration initiatives aimed at generating substantial value for our shareholders,” said Murray Nye, CEO of North American Niobium.”

All securities issued in connection with the Oversubscribed Offering are subject to a statutory hold period of four months plus a day ending on April 13, 2026, in accordance with applicable securities legislation and policies of the Canadian Securities Exchange (“CSE”).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.  The securities being offered have not been, nor will they be, registered under the 1933 Act or under any U.S. state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act, as amended, and applicable state securities laws.

ABOUT NORTH AMERICAN NIOBIUM AND CRITICAL MINERALS CORP.

North American Niobium and Critical Minerals Corp. is a North American mineral exploration company focused on the acquisition and development of precious, base, and critical mineral assets. Its portfolio includes the Silver Lake property in British Columbia’s Omineca Mining Division and a recently acquired land package in Quebec’s Grenville Province. The Quebec properties add exposure to rare earth elements (REE), niobium (Nb), and nickel-copper (Ni-Cu) occurrences, expanding the Company’s footprint into critical minerals that are strategically important for energy and defense applications.

ON BEHALF OF THE BOARD OF DIRECTORS:

Murray Nye
Chief Executive Officer

1055 West Georgia Street, Suite 1500
Vancouver, BC V6E 0B6
Canada

For further information, please contact:

Murray Nye, CEO
Email: [email protected]
Phone: +1 (647) 984-4204

CSE: NIOB
OTCQB: NIOMF
FSE:IOR

The Canadian Securities Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved the contents of this press release.

Forward-Looking Statements

This news release includes "forward-looking information" that is subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements may include but are not limited to the use of proceeds and available funds following the completion of the Oversubscribed Offering and are subject to all of the risks and uncertainties normally incident to such events. Investors are cautioned that any such statements are not guarantees of future events and that actual events or developments may differ materially from those projected in the forward-looking statements. Such forward-looking statements represent management's best judgment based on information currently available. No securities regulatory authority has either approved or disapproved of the contents of this news release. The Company undertakes no obligation to update publicly or otherwise revise any forward- looking statements, except as may be required by law.

LOS ANGELES, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 30, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired DeFi Technologies Inc. ("DeFi" or the "Company") (NASDAQ: DEFT) securities between May 12, 2025 and November 14, 2025 inclusive (the “Class Period”).

IF YOU SUFFERED A LOSS ON YOUR DEFI INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

What Happened?
On November 6, 2025, DeFi issued a press release reporting an arbitrage trade by its “specialized arbitrage trading desk” business segment, DeFi Alpha, stating its digital asset treasuries (“DATs”) “have absorbed or delayed a significant share of arbitrage opportunities over the past year.”

On this news, DeFi’s stock price fell $0.13, or 7.4%, to close at $1.62 per share on November 6, 2025, thereby injuring investors.
Then, on November 14, 2025, DeFi released its third quarter 2025 financial results, reporting a revenue decline of nearly 20% and significantly lowering its 2025 revenue forecast due to “a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025.” Additionally, the Company also disclosed that its CEO would be leaving his role and assuming an advisory position instead.

On this news, DeFi’s stock price fell $0.40, or 27.6%, over two consecutive trading days, to close at $1.05 per share on November 17, 2025, thereby injuring investors further.

What Is The Lawsuit About?
he complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) DeFi was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (2) DeFi had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (3) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (4) accordingly, Defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies' business and financial results; and (5) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired DeFi securities during the Class Period, you may move the Court no later than January 30, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Charles Linehan, Esq.,
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [email protected]
Telephone: 310-201-9150,
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact Us:
Glancy Prongay & Murray LLP,
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
Charles Linehan
Email: [email protected]
Telephone: 310-201-9150
Toll-Free: 888-773-9224
Visit our website at: www.glancylaw.com.